EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) on Friday, soared 8.36% from the previous trading day, before settling in for the closing price of $8.25. Within the past 52 weeks, EYPT’s price has moved between $3.91 and $13.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 16.27% over the last five years. The company achieved an average annual earnings per share of -28.05%. With a float of $59.89 million, this company’s outstanding shares have now reached $68.81 million.
The firm has a total of 165 workers. Let’s measure their productivity. In terms of profitability, gross margin is 93.29%, operating margin of -287.94%, and the pretax margin is -261.75%.
EyePoint Pharmaceuticals Inc (EYPT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of EyePoint Pharmaceuticals Inc is 12.97%, while institutional ownership is 96.94%. The most recent insider transaction that took place on May 19 ’25, was worth 29,950. In this transaction Director of this company bought 5,000 shares at a rate of $5.99, taking the stock ownership to the 36,500 shares. Before that another transaction happened on May 16 ’25, when Company’s Director bought 5,000 for $5.81, making the entire transaction worth $29,050. This insider now owns 31,500 shares in total.
EyePoint Pharmaceuticals Inc (EYPT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -28.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.51% during the next five years compared to 15.65% growth over the previous five years of trading.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Trading Performance Indicators
EyePoint Pharmaceuticals Inc (EYPT) is currently performing well based on its current performance indicators. A quick ratio of 7.79 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.41, a number that is poised to hit -0.81 in the next quarter and is forecasted to reach -2.91 in one year’s time.
Technical Analysis of EyePoint Pharmaceuticals Inc (EYPT)
Analysing the last 5-days average volume posted by the [EyePoint Pharmaceuticals Inc, EYPT], we can find that recorded value of 0.88 million was better than the volume posted last year of 0.84 million. As of the previous 9 days, the stock’s Stochastic %D was 95.55%. Additionally, its Average True Range was 0.57.
During the past 100 days, EyePoint Pharmaceuticals Inc’s (EYPT) raw stochastic average was set at 97.10%, which indicates a significant increase from 95.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.95% in the past 14 days, which was lower than the 85.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.16, while its 200-day Moving Average is $7.77. Now, the first resistance to watch is $9.26. This is followed by the second major resistance level at $9.59. The third major resistance level sits at $10.08. If the price goes on to break the first support level at $8.44, it is likely to go to the next support level at $7.95. Now, if the price goes above the second support level, the third support stands at $7.62.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Key Stats
Market capitalization of the company is 615.18 million based on 68,811K outstanding shares. Right now, sales total 43,270 K and income totals -130,870 K. The company made 24,450 K in profit during its latest quarter, and -45,200 K in sales during its previous quarter.
